Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo Journal Article


Authors: Cheung, N. K.; Guo, H.; Hu, J.; Tassev, D. V.; Cheung, I. Y.
Article Title: Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
Abstract: Murine IgG3 anti-GD2 antibody m3F8 has shown anti-neuroblastoma activity in Phase I/II studies, where antibody-dependent cell-mediated cytotoxicity (ADCC) played a key role. Humanization of m3F8 should circumvent human anti-mouse antibody (HAMA) response and enhance its ADCC properties to reduce dosing and pain side effect. Chimeric 3F8 (ch3F8) and humanized 3F8 (hu3F8-IgG1 and hu3F8-IgG4) were produced and purified by protein A affinity chromatography. In vitro comparison was made with m3F8 and other anti-GD2 antibodies in binding, cytotoxicity, and cross-reactivity assays. In GD2 binding studies by SPR, ch3F8 and hu3F8 maintained K(D) comparable to m3F8. Unlike other anti-GD2 antibodies, m3F8, ch3F8 and hu3F8 had substantially slower k(off.). Similar to m3F8, both ch3F8 and hu3F8 inhibited tumor cell growth in vitro, while cross-reactivity with other gangliosides was comparable to that of m3F8. Both peripheral blood mononuclear cell (PBMC)-ADCC and polymorphonuclear leukocytes (PMN)-ADCC of ch3F8 and hu3F8-IgG1 were more potent than m3F8. This superiority was consistently observed in ADCC assays, irrespective of donors or NK-92MI-transfected human CD16 or CD32, whereas complement mediated cytotoxicity (CMC) was reduced. As expected, hu3F8-IgG4 had near absent PBMC-ADCC and CMC. Hu3F8 and m3F8 had similar tumor-to-non tumor ratios in biodistribution studies. Anti-tumor effect against neuroblastoma xenografts was better with hu3F8-IgG1 than m3F8. In conclusion, humanizing m3F8 produced next generation anti-GD2 antibodies with substantially more potent ADCC in vitro and anti-tumor activity in vivo. By leveraging ADCC over CMC, they may be clinically more effective, while minimizing pain and HAMA side effects. A Phase I trial using hu3F8-IgG1 is ongoing.
Keywords: chimeric; humanized; monoclonal antibodies (MoAb); antibody-dependent cell-mediated cytotoxicity (ADCC); complement mediated cytotoxicity (CMC); peripheral blood mononuclear cells (PBMC); polymorphonuclear leukocytes (PMN)
Journal Title: OncoImmunology
Volume: 1
Issue: 4
ISSN: 2162-4011
Publisher: Landes Bioscience  
Date Published: 2012-07-01
Start Page: 477
End Page: 486
Language: English
PMCID: PMC3382886
PUBMED: 22754766
DOI: 10.4161/onci.19864
PROVIDER: manual
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Nai-Kong Cheung
    650 Cheung
  2. Irene Y Cheung
    96 Cheung
  3. Jian Hu
    15 Hu
  4. Hong-Fen Guo
    74 Guo
  5. Dimiter Tassev
    5 Tassev